Inovio Pharmaceuticals (GBM) AI Stock Analysis
Inovio Pharmaceuticals
(Frankfurt:GBM)
No summary available
Inovio Pharmaceuticals (GBM) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 100.18M
- Dividend Yield
- ―
- Average Volume (3M)
- 7,544
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.92
- Revenue Growth
- -100.00%
- EPS Growth
- 57.95%
- Country
- Germany
- Employees
- 112
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Inovio Pharmaceuticals Business Overview & Revenue Model
Company Description
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types...
Inovio Pharmaceuticals Earnings Call Summary
The call conveyed meaningful progress on the regulatory front (target PDUFA date, completed inspections, an FDA informal meeting) and tangible commercial/pipeline milestones (partner Phase III success, DPROT preclinical progress, Syneos engagement). Financially the company cut costs and completed an $18.3M equity offering that extends runway into late Q1 2027. However, material risks remain: near‑term liquidity is tight with an $18M projected Q3 burn, net loss improvement was substantially driven by a noncash warrant gain, regulatory uncertainties persist around accelerated approval eligibility and confirmatory trial design feedback, and competitive uptake of a rival product exists. Taken together, positives around regulatory momentum and platform validation are balanced by financing, regulatory, and execution risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management’s guidance centered on the INO-3.11 thousand BLA, which remains on track for the October 30, 2026 PDUFA under the FDA’s accelerated approval pathway after completion of late‑cycle review and all pre‑licensure inspections (one observation reported), with label negotiations expected to start in September, FDA feedback on the confirmatory trial design forthcoming, and an anticipated 7 years of orphan exclusivity if approved; financially, the company ended Q2 2026 with $36.7M in cash, completed a July equity offering that generated $18.3M net proceeds, estimates operational net cash burn of $18M for Q3 2026, and expects its cash to extend into late Q1 2027 (including prelaunch inventory and marketing spend across Q4 and Q1); operating expenses fell 19% YoY to $18.6M in Q2 (first‑half OpEx down 16%), Q2 net loss was $6.0M ($0.07/share) vs. $23.5M ($0.61/share) in Q2 2025 (helped by a $13.9M non‑cash warrant fair‑value gain), and commercial/prelaunch metrics noted ~200 patients treated with PAPZIMEOS (low single‑digit market penetration) and that 83% of PAPZIMEOS Phase I/II participants required ≥1 MRD surgery during the dosing window.
Inovio Pharmaceuticals Risk Analysis
Inovio Pharmaceuticals disclosed 58 risk factors in its most recent earnings report. Inovio Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksInovio Pharmaceuticals Peers Comparison
Overall Rating
AGEN51Neutral
ANIX49Neutral
ATOS48Neutral
TIL46Neutral
ONCY41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AGEN | 51Neutral | $314.78M | 8.76 | -38.12% | ― | 30.47% | ― |
| ANIX | 49Neutral | $114.03M | -9.93 | -70.44% | ― | ― | 10.04% |
| ATOS | 48Neutral | $21.16M | -0.47 | -102.99% | ― | ― | -28.83% |
| TIL | 46Neutral | $47.41M | -1.56 | -26.78% | ― | ― | 65.39% |
| ONCY | 41Neutral | $54.17M | -1.83 | 1020.21% | ― | ― | 2.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:GBM | Inovio Pharmaceuticals | 1.30 | -0.59 | -31.22% | |
| AGEN | Agenus Inc. | 7.15 | 2.94 | 69.83% | |
| ONCY | Oncolytics Biotech | 0.44 | -0.63 | -58.97% | |
| ATOS | Atossa Therapeutics, Inc. | 2.12 | -10.45 | -83.13% | |
| ANIX | Anixa Biosciences | 3.17 | -1.02 | -24.22% | |
| TIL | Instil Bio, Inc. | 6.83 | -7.98 | -53.88% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.